Q1 Earnings Forecast for SABS Issued By HC Wainwright

SAB Biotherapeutics, Inc. (NASDAQ:SABS) – Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of SAB Biotherapeutics in a report issued on Wednesday, January 29th. HC Wainwright analyst E. White expects that the company will earn ($1.35) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for SAB Biotherapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q2 2025 earnings at ($1.32) EPS, Q3 2025 earnings at ($1.31) EPS, Q4 2025 earnings at ($1.34) EPS, FY2025 earnings at ($5.31) EPS and FY2026 earnings at ($4.03) EPS.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Wednesday, November 6th. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05). SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.37%.

Several other brokerages have also recently issued reports on SABS. Chardan Capital restated a “buy” rating and set a $25.00 target price on shares of SAB Biotherapeutics in a research report on Wednesday. Craig Hallum began coverage on SAB Biotherapeutics in a report on Wednesday, October 9th. They issued a “buy” rating and a $11.00 target price for the company. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $12.40.

SAB Biotherapeutics Stock Down 2.7 %

NASDAQ SABS opened at $2.17 on Friday. The stock has a 50 day moving average price of $3.61 and a 200-day moving average price of $3.12. SAB Biotherapeutics has a one year low of $2.00 and a one year high of $6.30. The company has a current ratio of 3.69, a quick ratio of 3.69 and a debt-to-equity ratio of 0.09.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in SAB Biotherapeutics stock. Kovitz Investment Group Partners LLC bought a new stake in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 19,201 shares of the company’s stock, valued at approximately $52,000. Kovitz Investment Group Partners LLC owned 0.21% of SAB Biotherapeutics at the end of the most recent reporting period. 7.82% of the stock is currently owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.